PURPOSE: The @entity9513 gatekeeper mutation in the @entity470 is acquired by some @entity470 -mutant @entity1149 ( @entity1149 ) as they become resistant to selective @entity4149 kinase inhibitors (TKI). As third-generation @entity470 TKIs that overcome @entity9513 -associated resistance become available, noninvasive approaches to @entity9513 detection will become critical to guide management. EXPERIMENTAL DESIGN: As part of a multi-institutional Stand-Up-To-Cancer collaboration, we performed an exploratory analysis of 40 @entity1 with @entity470 -mutant @entity5 progressing on @entity470 TKI therapy. We compared the @entity9513 genotype from @entity5 biopsies with analysis of simultaneously collected circulating @entity5 cells (CTC) and circulating @entity5 DNA (ctDNA). RESULTS: @entity9513 genotypes were successfully obtained in 30 (75%) @entity5 biopsies, 28 (70%) CTC samples, and 32 (80%) ctDNA samples. The resistance-associated mutation was detected in 47% to 50% of @entity1 using each of the genotyping assays, with concordance among them ranging from 57% to 74%. Although CTC- and ctDNA-based genotyping were each unsuccessful in 20% to 30% of cases, the two assays together enabled genotyping in all @entity1 with an available blood sample, and they identified the @entity9513 mutation in 14 (35%) @entity1 in whom the concurrent biopsy was negative or indeterminate. CONCLUSIONS: Discordant genotypes between @entity5 biopsy and blood-based analyses may result from technological differences, as well as sampling different @entity5 cell populations. The use of complementary approaches may provide the most complete assessment of each @entity1 's @entity5 , which should be validated in predicting response to @entity9513 -targeted inhibitors. Clin Cancer Res; 1-8.   2015 AACR.

Detection of XXXX , the Acquired Resistance @entity470 Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity470 :: ('1956', 'Gene') :: ['EGFR'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer', 'tumors'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancers'] @entity4149 :: ('D014443', 'Chemical') :: ['tyrosine'] @entity9513 :: ('p|SUB|T|790|M', 'ProteinMutation') :: ['T790M']
@entity9513 :: (p|SUB|T|790|M,ProteinMutation) :: ['T790M']
